Eli Lilly (LLY)

The Danish pharmaceutical company is fighting a competitive war on several fronts.

A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?

Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.

The company is struggling with several headwinds as it works to develop its obesity plan.

Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped.

The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk.

Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 monthly?

The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what investors should know.

The company, which went public in May, provides AI-powered physical therapy through a mobile application.

Are you brave enough to catch this falling knife?

Inspire Medical stock falls as Q2 earnings beat is overshadowed by guidance cut and slower U.S. rollout of its newly approved Inspire V system.

Whether you're looking for growth stocks, dividend stocks, or artificial intelligence stocks, there is something for you in this incredible list.

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings

The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug.

A significant trading signal flashed for Eli Lilly (LLY) at a price of $755.87, after which LLY rose up to 1.8% and closed near its intra-day high.

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

It's not too late to invest in this company.

This weight loss drugmaker may be significantly undervalued right now.

US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics.

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,

Here are hot stocks to buy in a hot month.

Zepbound could benefit handsomely if an apparently planned government program is implemented.